24.06.2013 - British GlaxoSmithKline is participating in the new Kurma Biofund II in France. €17.5m of the €44m raised so far comes from GSK.
In a bid to identify promising new targets and drugs, British Pharma GlaxoSmithKline gains a foothold in a rare diseases venture fund. GSK said last week it will invest €17.5m in the Kurma Biofund II. It is the first venture capital fund dedicated to financing innovation in the rare diseases field through working with a network of European research institutes. Lead investor is the French firm Kurma Life Sciences Partners, with other backers including CDC Enterprises, Idinvest Partners and New Enterprise Associates. So far €44m has been raised. In April, GSK took a another bigger step when it decided to team up with Avalon Ventures in a deal worth up to €375m to fund ten drug discovery start-ups over the next three years (also see EuroBiotechNews Special May/2013).
Kurma Biofund I, valued at €51m, is still managed by Paris-based Kurma Life Sciences Partners. Like Biofund II this fund seeks the establishment of a new economic model for the financing of innovation – based on strategic partnerships with highly reputable biotechnology and medical research centers in France and the rest of Europe. Whereas Biofund II is targeted to rare diseases, Biofund I is largely concerned with life sciences and the health sector in general. Biofund I included enterprises ABM Medical, AM Pharma, Blink, Indigix, Key Neurosciences, Meiogenix, Pathoquest, Safe Orthopaedics, Umecrine and Zealand Pharma. Zealand recently made the news with its Sanofi-co-development. Since May Lyxumia has a European marketing authorisation as a diabetes therapy.
03.07.2015 Biotech giant Biogen is investing CHF 1bn in a new pharmaceutical production plant in the Swiss town of Luterbach. Noted as one of the world’s oldest biotech firms, the new plant will create up to 400 jobs.
02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.
30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.
24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.
22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.
12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.
METTLER TOLEDO now offers a new family of high-precision weighing platforms that provide superior accuracy and reliability in harsh industrial conditions with flexibility to be used for many applications. more